Randomized Trialmoderate evidence
Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.
The Lancet. Oncology·September 11, 2026·PMID 42727592
Why it mattersLung cancer survival remains poor, and PRO monitoring may offer a scalable way to detect symptoms early and improve outcomes. This real-world, multicentre trial extends prior evidence from advanced cancer to all stages, suggesting that integrating weekly electronic symptom assessments into routine oncology care could meaningfully prolong survival.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled